Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) Sees Significant Decline in Short Interest

Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) was the target of a large drop in short interest during the month of January. As of January 30th, there was short interest totaling 693,745 shares, a drop of 97.6% from the January 15th total of 29,166,975 shares. Based on an average daily trading volume, of 1,796,547 shares, the days-to-cover ratio is presently 0.4 days. Approximately 34.8% of the shares of the company are sold short. Approximately 34.8% of the shares of the company are sold short. Based on an average daily trading volume, of 1,796,547 shares, the days-to-cover ratio is presently 0.4 days.

Aspire Biopharma Stock Down 2.1%

ASBP stock traded down $0.03 during midday trading on Tuesday, reaching $1.41. The company’s stock had a trading volume of 346,054 shares, compared to its average volume of 1,555,450. The business’s 50-day simple moving average is $3.21 and its 200-day simple moving average is $10.22. The stock has a market cap of $3.79 million, a PE ratio of -0.07 and a beta of 0.82. Aspire Biopharma has a 52 week low of $1.26 and a 52 week high of $632.00.

Aspire Biopharma (NASDAQ:ASBP) last issued its earnings results on Friday, November 14th. The company reported ($1.60) earnings per share (EPS) for the quarter. The business had revenue of $0.00 million during the quarter.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. CIBC Bancorp USA Inc. bought a new stake in shares of Aspire Biopharma during the 3rd quarter worth approximately $28,000. Jane Street Group LLC lifted its position in Aspire Biopharma by 625.8% during the second quarter. Jane Street Group LLC now owns 152,552 shares of the company’s stock worth $41,000 after acquiring an additional 131,533 shares during the last quarter. Optivise Advisory Services LLC grew its holdings in Aspire Biopharma by 120.9% in the 2nd quarter. Optivise Advisory Services LLC now owns 235,106 shares of the company’s stock valued at $63,000 after buying an additional 128,660 shares in the last quarter. Finally, Crewe Advisors LLC increased its position in Aspire Biopharma by 100.0% during the second quarter. Crewe Advisors LLC now owns 626,854 shares of the company’s stock worth $169,000 after acquiring an additional 313,427 shares during the period. Institutional investors and hedge funds own 19.17% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the company. Wall Street Zen raised Aspire Biopharma to a “sell” rating in a research report on Saturday, January 17th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Aspire Biopharma in a research report on Wednesday, January 21st. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, Aspire Biopharma presently has an average rating of “Sell”.

About Aspire Biopharma

Aspire Biopharma Inc is a specialty pharmaceutical company dedicated to developing and commercializing inhaled therapeutics for cardiopulmonary emergencies and respiratory diseases. The firm leverages proprietary formulation and drug-delivery technologies to repurpose established active pharmaceutical ingredients, aiming to enhance onset of action and improve patient convenience in acute settings. Aspire’s focus on pulmonary administration differentiates its approach from traditional oral or injectable treatments for asthma, allergic reactions, and other respiratory conditions.

The company’s lead asset is a reformulated metered-dose inhaler version of epinephrine designed to serve as an over-the-counter or prescription rescue therapy for acute bronchospasm and anaphylaxis.